Gossamer Bio Files 2024 10-K
Ticker: GOSS · Form: 10-K · Filed: 2025-03-13T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
Gossamer Bio dropped its 2024 10-K. Check financials for the year ending Dec 31, 2024.
AI Summary
Gossamer Bio, Inc. filed its 2024 10-K on March 13, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, incorporated in Delaware, operates in the Pharmaceutical Preparations sector. Key financial details and operational highlights for 2024 are presented in this annual report.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Gossamer Bio's financial health, operational performance, and strategic direction for the past fiscal year.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Gossamer Bio faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 — Fiscal Year (The period covered by the 10-K filing.)
- 1231 — Fiscal Year End (Indicates the end date of the reporting period.)
- 001-38796 — SEC File Number (Unique identifier for the company's filings with the SEC.)
Key Players & Entities
- Gossamer Bio, Inc. (company) — Filer of the 10-K report
- 2024-12-31 (date) — Fiscal year end
- 2025-03-13 (date) — Filing date of the 10-K
- San Diego, CA (location) — Company headquarters
FAQ
What is Gossamer Bio, Inc.'s primary business sector?
Gossamer Bio, Inc. operates in the Pharmaceutical Preparations sector, with Standard Industrial Classification code 2834.
When was the 10-K filing submitted to the SEC?
The 10-K filing was submitted on March 13, 2025.
What is the fiscal year end for Gossamer Bio, Inc.?
The company's fiscal year ends on December 31.
Where is Gossamer Bio, Inc. headquartered?
Gossamer Bio, Inc. is headquartered in San Diego, CA, with a business and mailing address at 3115 Merryfield Row, Suite 120.
What is the SEC file number for Gossamer Bio, Inc.?
The SEC file number for Gossamer Bio, Inc. is 001-38796.
From the Filing
0001728117-25-000021.txt : 20250313 0001728117-25-000021.hdr.sgml : 20250313 20250313160137 ACCESSION NUMBER: 0001728117-25-000021 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250313 DATE AS OF CHANGE: 20250313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gossamer Bio, Inc. CENTRAL INDEX KEY: 0001728117 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 475461709 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38796 FILM NUMBER: 25735631 BUSINESS ADDRESS: STREET 1: 3115 MERRYFIELD ROW STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 684-1300 MAIL ADDRESS: STREET 1: 3115 MERRYFIELD ROW STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 10-K 1 goss-20241231.htm 10-K goss-20241231 false 2024 FY 0001728117 http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202006Member P2Y http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent 0.0616095 33 P1Y iso4217:USD xbrli:shares iso4217:USD xbrli:shares goss:segment goss:security goss:tranche xbrli:pure goss:tradingDay goss:vote goss:day utr:sqft goss:month goss:performanceObligation goss:license 0001728117 2024-01-01 2024-12-31 0001728117 2024-06-28 0001728117 2025-03-06 0001728117 2024-10-01 2024-12-31 0001728117 2024-12-31 0001728117 2023-12-31 0001728117 us-gaap:LicenseAndServiceMember 2024-01-01 2024-12-31 0001728117 us-gaap:LicenseAndServiceMember 2023-01-01 2023-12-31 0001728117 us-gaap:LicenseAndServiceMember 2022-01-01 2022-12-31 0001728117 goss:RevenueFromContractsWithCollaboratorsMember 2024-01-01 2024-12-31 0001728117 goss:RevenueFromContractsWithCollaboratorsMember 2023-01-01 2023-12-31 0001728117 goss:RevenueFromContractsWithCollaboratorsMember 2022-01-01 2022-12-31 0001728117 2023-01-01 2023-12-31 0001728117 2022-01-01 2022-12-31 0001728117 us-gaap:CommonStockMember 2021-12-31 0001728117 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001728117 us-gaap:RetainedEarningsMember 2021-12-31 0001728117 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001728117 2021-12-31 0001728117 2021-01-01 2021-12-31 0001728117 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001728117 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0001728117 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-12-31 0001728117 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001728117 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001728117 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001728117 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001728117 us-gaap:CommonStockMember 2022-12-31 0001728117 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001728117 us-gaap:RetainedEarningsMember 2022-12-31 0001728117 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001728117 2022-12-31 0001728117 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001728117 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001728117 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001728117 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001728117 us-gaap:CommonStockMember 2023-12-31 0001728117 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001728117 us-gaap:RetainedEarningsMember 2023-12-31 0001728117 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001728117 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001728117 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001728117 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001728117 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001728117 us-gaap:CommonStockMember 2024-12-31 0001728117 us-gaap:AdditionalPaidInCapi